The mechanisms of lncRNA GAS5 in cardiovascular cells and its potential as novel therapeutic target. (25th November 2020)

• Record Type: Journal Article
• Authors: Jiang, Xiaoying; Ning, Qilan
• Is Part Of: Journal of drug targeting. Volume 28:Number 10(2020)
• Page Start: 1012
• Page End: 1017
• Publication Date: 2020-11-25
• Subjects: long noncoding RNAs -- GAS5 -- cardiovascular cells; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2020.1769108
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: Long noncoding RNAs (lncRNAs) are a large class of non (protein)-coding RNAs, which are longer beyond 200 nucleotides. LncRNA GAS5 is widely considered as a tumour suppressor in cell proliferation, apoptosis, cell migration and invasion of tumour cells. Recently, a growing body of evidences indicated that GAS5 was also widely involved in the pathologic process of cardiovascular cells, including regulation of apoptosis and inflammatory injury of cardiomyocytes; proliferation, apoptosis, autophagy and angiogenesis of endothelial cells; and proliferation, migration, apoptosis and differentiation of VSMCs. In this regard, we summarised current studies of GAS5 in cardiovascular cells, which shed light on not only our understanding of the mechanisms of GAS5 in cardiovascular cells but also understanding of the potential of GAS5 as novel therapeutic target.